Psychiatry and Neurology, Neurology · Shreveport, LA
NPI
1730381179
Since 2007
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1541 Kings Hwy
Shreveport, LA, 71103
Phone (318) 626-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$31K
552 services
Medicare patients, 2024
167
Average age 64
Drug cost, 2024
$5.2M
3,208 prescriptions
Company payments, 2025
$2,518
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Erik Burton was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 199 times for 112 patients. In total Erik Burton billed 552 services in 20 codes, and Medicare paid $31K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-08-21.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 199 | 112 | $11.59 | $2,306 |
| 99215 Office E&M - Established | Office | 92 | 65 | $92.78 | $8,536 |
| 99214 Office E&M - Established | Office | 87 | 70 | $67.43 | $5,867 |
| 99233 Hospital E&M - Subsequent | Facility | 54 | 20 | $88.51 | $4,780 |
| 99213 Office E&M - Established | Office | 32 | 27 | $46.81 | $1,498 |
| 99223 Hospital E&M - Initial | Facility | 24 | 24 | $127.60 | $3,062 |
| 99232 Hospital E&M - Subsequent | Facility | 24 | 14 | $56.23 | $1,350 |
By year: 2022 $32K for 374 services; 2023 $32K for 384 services; 2024 $31K for 552 services.
Medicare prescription drug claims, 2024
In 2024, the drug Erik Burton prescribed most often to Medicare patients was Kesimpta Pen (Ofatumumab), with 231 prescriptions and refills. In total Erik Burton wrote 3,208 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Kesimpta Pen Ofatumumab | 231 | 231 | 29 | $2.1M |
| Dalfampridine Er Dalfampridine | 220 | 245 | 35 | $91K |
| Baclofen Generic | 198 | 242 | 37 | $3,372 |
| Gabapentin Generic | 191 | 236 | 39 | $2,773 |
| Pregabalin Generic | 133 | 149 | 26 | $2,050 |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 115 | 115 | 19 | $2,980 |
| Clonazepam Generic | 95 | 95 | 18 | $539 |
| Duloxetine Hcl Generic | 73 | 121 | 21 | $968 |
| Myrbetriq Mirabegron | 72 | 80 | Under 11 | $29K |
| Mayzent Siponimod | 62 | 62 | Under 11 | $585K |
| Nurtec Odt Rimegepant Sulfate | 60 | 62 | 13 | $89K |
| Tizanidine Hcl Generic | 58 | 66 | 18 | $782 |
| Meloxicam Generic | 57 | 77 | 15 | $329 |
| Tolterodine Tartrate Er Tolterodine Tartrate | 55 | 77 | 11 | $2,874 |
| Cyclobenzaprine Hcl Generic | 50 | 68 | 17 | $257 |
Brand drugs: 716 claims; generic drugs: 2,492 claims; opioid claims: 48.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Erik Burton $2,518 ($2,518 in general payments such as food, travel and fees) from 25 companies. The largest payer was Abbvie Inc. with $443.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 33 | $443 |
| ACADIA Pharmaceuticals Inc ACAD | 49 | $311 |
| Pfizer Inc. PFE | 23 | $295 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $232 |
| Genentech USA, Inc. ROG.SW | 10 | $199 |
| Biogen, Inc. BIIB | 4 | $87.46 |
| EMD Serono, Inc. MRK.DE | 3 | $81.9 |
| TG Therapeutics, Inc. TGTX | 4 | $81.89 |
| Lilly USA, LLC LLY | 5 | $81.22 |
| UCB, Inc. UCB.BR | 3 | $76.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.